1. Market Research
  2. > All Companies
  3. > Bioheart, Inc. (BHRT) - Medical Equipment - Deals and Alliances Profile

Summary

Bioheart, Inc. (Bioheart) is a biotechnology company, which focuses on developing cell technologies for the treatment of cardiovascular and related diseases. Its product candidates include Myocell, Myocell SDF-1, Myocath, and Adipocell. Myocell is a muscle stem cell theraphy that intends to improve the cardiac function of a damaged heart after a severe heart attack. Myocell SDF-1 is an improved version of Myocell. Myocath is a disposable needle injection catheter that is used to deliver biologic solutions to a targeted treatment site within the inner wall of the heart. Adipocell is used to treat patients with chronic ischemic cardiomyopathy. Bioheart is headquartered in Florida, the US.

Bioheart, Inc. (BHRT) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Bioheart, Inc. (BHRT) - Medical Equipment - Deals and Alliances Profile
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Bioheart, Inc., Medical Equipment, Deals By Year, 2009 to YTD 2015 6
Bioheart, Inc., Medical Equipment Deals By Type, 2009 to YTD 2015 7
Bioheart, Inc., Medical Equipment, Deals By Region, 2009 to YTD 2015 8
Bioheart, Inc., Medical Equipment, Deals By Market, 2009 to YTD 2015 9
Bioheart, Inc., Medical Equipment, Deals Summary, 2009 to YTD 2015 10
Bioheart, Inc., Medical Equipment, Deal Details 11
Partnerships 11
Bioheart Extends Licensing Agreement With Airspeed Equity 11
Bioheart Enters Into Licensing Agreement With Airspeed Equity 12
Bioheart Enters Into Licensing Agreement With Ageless Regenerative Institute For Adipose Cell Technology 13
Equity Offering 14
Bioheart to Raise USD3 Million in Private Placement of Shares 14
Bioheart Completes Private Placement Of Shares For US$3 Million 15
Bioheart Completes Private Placement Of Shares 16
Bioheart Announces Private Placement Of Shares For US$2 Million 17
Bioheart Receives Equity Investment From AnC Bio Holdings 18
Bioheart Completes Private Placement Of US$2.9 Million 19
Bioheart Announces Private Placement Of US$7 Million 20
Debt Offering 21
Bioheart Raises USD3 Million in Private Placement of Notes 21
Acquisition 22
Bioheart to Acquire Pavillion Scientific 22
Bioheart to Invest in Ascyrus Medical 23
Bioheart, Inc. - Key Competitors 24
Key Employees 25
Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Strategy And Business Planning 27
Sep 24, 2014: Bioheart Announces Successful Grand Opening of Facility in South Africa 27
Sep 16, 2014: Bioheart Announces Grand Opening of Facility in South Africa 28
Financial Announcements 29
May 06, 2015: Bioheart Highlights Positive First Quarter Results 29
Aug 07, 2014: Bioheart Releases Q2 Financial Information Showing Growth 30
May 15, 2014: Bioheart Reports Significant Revenue Increases 31
Corporate Communications 32
Jan 29, 2015: Bioheart Strengthens Management Team with Appointment of Martin E. Schmieg as President of Vetbiologics 32
Product News 33
Sep 01, 2014: Biventricular pacing disappoints in BIOPACE trial 33
Other Significant Developments 34
Aug 27, 2015: Bioheart to Change Name to U.S. Stem Cell, Inc. 34
Feb 24, 2014: Bioheart Reports Positive Update on CEO Mike Tomas 35
Jan 29, 2014: Bioheart Announces First Adipose Derived Stem Cell Implantation In Azerbaijan 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Bioheart, Inc., Medical Equipment, Key Facts, 2014 1
Bioheart, Inc., Medical Equipment, Deals Summary, 2009 to YTD 2015 1
Bioheart, Inc., Medical Equipment, Deals By Year, 2009 to YTD 2015 6
Bioheart, Inc., Medical Equipment Deals By Type, 2009 to YTD 2015 7
Bioheart, Inc., Medical Equipment, Deals By Region, 2009 to YTD 2015 8
Bioheart, Inc., Deals By Market, 2009 to YTD 2015 9
Bioheart, Inc., Medical Equipment, Deals Summary, 2009 to YTD 2015 10
Bioheart Extends Licensing Agreement With Airspeed Equity 11
Bioheart Enters Into Licensing Agreement With Airspeed Equity 12
Bioheart Enters Into Licensing Agreement With Ageless Regenerative Institute For Adipose Cell Technology 13
Bioheart to Raise USD3 Million in Private Placement of Shares 14
Bioheart Completes Private Placement Of Shares For US$3 Million 15
Bioheart Completes Private Placement Of Shares 16
Bioheart Announces Private Placement Of Shares For US$2 Million 17
Bioheart Receives Equity Investment From AnC Bio Holdings 18
Bioheart Completes Private Placement Of US$2.9 Million 19
Bioheart Announces Private Placement Of US$7 Million 20
Bioheart Raises USD3 Million in Private Placement of Notes 21
Bioheart to Acquire Pavillion Scientific 22
Bioheart to Invest in Ascyrus Medical 23
Bioheart, Inc., Key Competitors 24
Bioheart, Inc., Key Employees 25

List of Figures
Bioheart, Inc., Medical Equipment, Deals by Type, 2009 to YTD 2015 1
Bioheart, Inc., Medical Equipment, Deals By Year, 2009 to YTD 2015 1
Bioheart, Inc., Medical Equipment, Deals By Region, 2009 to YTD 2015 1
Bioheart, Inc., Medical Equipment, Deals By Market, 2009 to YTD 2015 1
Bioheart, Inc., Medical Equipment, Deals By Year, 2009 to YTD 2015 6
Bioheart, Inc., Medical Equipment, Deals by Type, 2009 to YTD 2015 7
Bioheart, Inc., Medical Equipment, Deals By Region, 2009 to YTD 2015 8
Bioheart, Inc., Medical Equipment, Deals by Market, 2009 to YTD 2015 9

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015

  • $ 2 000
  • Company report
  • October 2015
  • by Global Markets Direct

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015’, provides an overview of the Chemotherapy ...

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015

  • $ 2 000
  • Company report
  • December 2015
  • by Global Markets Direct

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015’, provides an overview of the Cytomegalovirus ...

Critical Limb Ischemia - Pipeline Review, H2 2015

Critical Limb Ischemia - Pipeline Review, H2 2015

  • $ 2 000
  • Company report
  • December 2015
  • by Global Markets Direct

Critical Limb Ischemia - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Critical Limb Ischemia - Pipeline Review, H2 2015’, provides an overview of the Critical Limb Ischemia’s therapeutic ...

Ischemia - Pipeline Review, H2 2015

December 2015 $ 2 000

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.